脑脊液可溶性程序性死亡配体1是原发性中枢神经系统淋巴瘤有用的预后生物标志物
该研究用酶联免疫吸附试验检测46例原发性中枢神经系统淋巴瘤(PCNSL)患者脑脊液可溶性PD-L1(sPD-L1)和sPD-L2浓度,对照组为153例其他脑肿瘤、炎症/感染或神经退行性疾病患者。仅脑脊液sPD-L1在PCNSL患者中显著高于对照组,且诊断鉴别能力优于sPD-L2;高sPD-L1与高血清乳酸脱氢酶、软脑膜受累和深部脑受累相关,可预测不良生存,其治疗后动态变化可预测复发时间。
要点
- PCNSL患者脑脊液sPD-L1显著高于对照组,sPD-L2无显著差异。
- 脑脊液sPD-L1诊断PCNSL的总体鉴别能力优于sPD-L2。
- 高脑脊液sPD-L1与高血清LDH、软脑膜及深部脑受累相关,可预测不良生存。
核心结论
- 脑脊液sPD-L1是有前景的预后生物标志物,提示PD-L1阻断在PCNSL中具有治疗潜力。
研究设计与样本
- 研究纳入46例PCNSL患者,采用酶联免疫吸附试验测定脑脊液sPD-L1和sPD-L2浓度。
- 对照组由153例其他脑肿瘤、炎症/感染状态或神经退行性疾病患者组成。
主要发现
- 仅脑脊液sPD-L1水平在PCNSL患者中显著高于对照组。
- 脑脊液sPD-L1诊断PCNSL的总体鉴别能力优于脑脊液sPD-L2。
- 与脑脊液sPD-L1低的PCNSL患者相比,高sPD-L1患者中高血清乳酸脱氢酶、软脑膜受累和深部脑受累者更多。
- 脑脊液sPD-L1可预测PCNSL不良生存,而sPD-L2不能。
- 脑脊液sPD-L1水平与疾病状态相关,治疗后动态变化可预测复发时间。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The increased expression of programmed death-ligands 1 and 2 (PD-L1 and PD-L2, respectively) on tumour cells contributes to immune evasion, suggesting that these proteins are attractive therapeutic targets. This study aimed to evaluate the validity of cerebrospinal fluid (CSF) soluble PD-L1 (sPD-L1) and soluble PD-L2 (sPD-L2) as biomarkers for primary central nervous system lymphoma (PCNSL). We determined the CSF concentrations of sPD-L1 and sPD-L2 in 46 patients with PCNSL using enzyme-linked immunosorbent assays (ELISAs). A control group comprised 153 patients with other brain tumours, inflammatory/infectious status, or neurodegenerative diseases. Only CSF sPD-L1 levels were significantly higher in patients with PCNSL relative to the controls. CSF sPD-L1 also exhibited superior overall discrimination performance compared to CSF sPD-L2 in diagnosing PCNSL. Compared with patients with PCNSL with low CSF sPD-L1 levels, more patients with high levels had high serum lactate dehydrogenase levels, leptomeningeal involvement, and deep-brain involvement. Furthermore, CSF sPD-L1 could predict poor survival in PCNSL but CSF sPD-L2 could not. Intriguingly, CSF sPD-L1 levels were correlated with disease status and their dynamic changes post treatment could predict time to relapse. In conclusion, this study identified CSF sPD-L1 as a promising prognostic biomarker, indicating a therapeutic potential of PD-L1 blockade in PCNSL.
引用
- Cheng CL, Yao CY, Huang PH, et al. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma. Br J Haematol. 2022. PMID: 36480431. doi:10.1111/bjh.18598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。